Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity

Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works

GLYCOBIOLOGY

Rademacher, T. W., Parekh, R. B., & Dwek, R. A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004033 · Cited by 1,144 · see citing works

Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity

Urlaub, G., & Chasin, L. A. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.4216 · Cited by 876 · see citing works

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 685 · see citing works

Establishment of <i>FUT8</i> knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity

Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572 · see citing works

Glycosylation of Recombinant Antibody Therapeutics

Jefferis, R. (2005) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526 · see citing works

Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson

Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440 · see citing works

Crystallographic structure studies of an IgG molecule and an Fc fragment

Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M., & Palm, W. (1976) · Nature · doi:10.1038/264415a0 · Cited by 422 · see citing works

The Structure of a Human Type III Fcγ Receptor in Complex with Fc*

Radaev, S., Motyka, S., Fridman, W., Sautès-Fridman, C., & Sun, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100350200 · Cited by 362 · see citing works

The Carbohydrate at FcγRIIIa Asn-162

Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 355 · see citing works

Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa

Okazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., Tsumoto, K., Kumagai, I., & Shitara, K. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.007 · Cited by 337 · see citing works

IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

Jefferis, R., Lund, J., & Pound, J. D. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01188.x · Cited by 330 · see citing works

Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., & Shitara, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2068 · Cited by 327 · see citing works

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · see citing works

Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level

Ober, R. J., Martinez, C., Lai, X., Zhou, J., & Ward, E. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402970101 · Cited by 258 · see citing works

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

Tao, M., Smith, R. I., & Morrison, S. L. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.2.661 · Cited by 251 · see citing works

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.009 · Cited by 244 · see citing works

Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism

Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227 · see citing works

Interaction sites on human IgG-Fc for FcγR: current models

Jefferis, R., & Lund, J. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00019-6 · Cited by 220 · see citing works

Purification and cDNA Cloning of Porcine Brain GDP-L-Fuc:N-Acetyl-β-D-Glucosaminide α1→6Fucosyltransferase

Uozumi, N., Yanagidani, S., Miyoshi, E., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27810 · Cited by 216 · see citing works

Structural and numerical variations of the carbohydrate moiety of immunoglobulin G.

Mizuochi, T., Taniguchi, T., Shimizu, A., & Kobata, A. (1982) · Journal of Immunology · doi:10.4049/jimmunol.129.5.2016 · Cited by 211 · see citing works

Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa

Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206 · see citing works

Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.

Wright, A. M., & Morrison, S. L. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.3.1087 · Cited by 192 · see citing works

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187 · see citing works

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA

Mori, K., Kuni‐Kamochi, R., Yamane‐Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20326 · Cited by 174 · see citing works

Purification and cDNA Cloning of GDP-L-Fuc:N-Acetyl- -D-Glucosaminide: 1-6 Fucosyltransferase ( 1-6 FucT) from Human Gastric Cancer MKN45 Cells

Yanagidani, S., Uozumi, N., Ihara, Y., Miyoshi, E., Yamaguchi, N., & Taniguchi, N. (1997) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021631 · Cited by 167 · see citing works

Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells

Wright, A. M., & Morrison, S. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3393 · Cited by 158 · see citing works

A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis

Papac, D. I. (1998) · Glycobiology · doi:10.1093/glycob/8.5.445 · Cited by 150 · see citing works

Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC

Kanda, Y., Yamane‐Ohnuki, N., Sakai, N., Yamano, K., Nakano, R., Inoue, M., Misaka, H., Iida, S., Wakitani, M., Konno, Y., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20880 · Cited by 115 · see citing works

In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure

Wright, A. M., Sato, Y., Okada, T., Chang, K. H., Endo, T., & Morrison, S. L. (2000) · Glycobiology · doi:10.1093/glycob/10.12.1347 · Cited by 111 · see citing works

Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns

Harada, H., Kamei, M., Tokumoto, Y., et al. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90507-0 · Cited by 102 · see citing works

Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes.

Thornburg, R. W., Day, J. F., Baynes, J., et al. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43646-0 · Cited by 98 · see citing works

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering

Schuster, M., Umaña, P., Ferrara, C., Brünker, P., Gerdes, C. A., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4212 · Cited by 91 · see citing works

Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis

Kamoda, S., Nomura, C., Kinoshita, M., Nishiura, S., Ishikawa, R., Kakehi, K., Kawasaki, N., & Hayakawa, T. (2004) · Journal of Chromatography A · doi:10.1016/s0021-9673(04)01399-8 · Cited by 86 · see citing works

Two chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose

Ripka, J., Adamany, A. M., & Stanley, P. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90031-7 · Cited by 81 · see citing works

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region

Natsume, A., Wakitani, M., Yamane‐Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.07.025 · Cited by 65 · see citing works

Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway

Crispin, M., Harvey, D. J., Chang, V. T.-C., Yu, C., Aricescu, A. R., Jones, E. Y., Davis, S. J., Dwek, R. A., & Rudd, P. M. (2006) · Glycobiology · doi:10.1093/glycob/cwj119 · Cited by 63 · see citing works

Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation

Rothman, R. J., PERUSSIA, B., Herlyn, D., et al. (1989) · Molecular Immunology · doi:10.1016/0161-5890(89)90055-2 · Cited by 62 · see citing works

Comparability Testing of a Humanized Monoclonal Antibody (Synagis®) to Support Cell Line Stability, Process Validation, and Scale-Up for Manufacturing

Schenerman, M. A., Hope, J. N., Kletke, C., et al. (1999) · Biologicals · doi:10.1006/biol.1999.0179 · Cited by 59 · see citing works

Core fucosylation of high-mannose-type oligosaccharides in GlcNAc transferase I-deficient (Lec1) CHO cells

Lin, A. I., Philipsberg, G. A., & Haltiwanger, R. S. (1994) · Glycobiology · doi:10.1093/glycob/4.6.895 · Cited by 57 · see citing works

Control of carbohydrate processing: the lec1A CHO mutation results in partial loss of N-acetylglucosaminyltransferase I activity.

Stanley, P., & Chaney, W. G. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.6.1204 · Cited by 44 · see citing works

Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody

Nakamura, K., Tanaka, Y., Fujino, I., Hirayama, N., Shitara, K., & Hanai, N. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00021-9 · Cited by 42 · see citing works

Glycosylation of human IgG antibodies: Relevance to therapeutic applications

Jefferis, R. (2002) · Cited by 40 · see citing works

Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3

Ohta, S., Honda, A., Tokutake, Y., Yoshida, H., & Hanai, N. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01740908 · Cited by 31 · see citing works

Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions

Awwad, M., Strome, P. G., Gilman, S. C., et al. (1994) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517166 · Cited by 18 · see citing works

Inhibition of processing of asparagine-linked carbohydrate chains on IgG2a by using swainsonine has no influence upon antibody effector functions in vitro.

Nose, M., & Heyman, B. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.3.910 · Cited by 12 · see citing works

Evidence for a role of accessible galactosyl or mannosyl residues of Fc domain in the in vivo clearance of IgG antibody-coated autologous erythrocytes in the rat

Malaise, M., Hoyoux, C., Franchimont, P., et al. (1990) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(90)90059-y · Cited by 4 · see citing works

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467 · see citing works

Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins

Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Determination of critical quality attributes for monoclonal antibodies using quality by design principles

Alt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294 · see citing works

Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans

Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203 · see citing works

Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms

Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186 · see citing works

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148 · see citing works

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

Bumbaca, D., Boswell, C. A., Fielder, P. J., & Khawli, L. A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9369-y · Cited by 119 · see citing works

Glycosylation and Fc Receptors

Hayes, J. M., Cosgrave, E. F. J., Struwe, W. B., Wormald, M., Davey, G. P., Jefferis, R., & Rudd, P. M. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-319-07911-0_8 · Cited by 110 · see citing works

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110 · see citing works

Multi-angle effector function analysis of human monoclonal IgG glycovariants

Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143520 · Cited by 101 · see citing works

Antibody glycoengineering strategies in mammalian cells

Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 94 · see citing works

Glycoengineering Chinese hamster ovary cells: a short history

Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37 · see citing works

Choice of host cell line is essential for the functional glycosylation of the Fc region of human IgG1 inhibitors of influenza B viruses

Blundell, P. A., Lu, D., Dell, A., Haslam, S., & Pleass, R. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901145 · Cited by 29 · see citing works

Understanding the effect of increased cell specific productivity on galactosylation of monoclonal antibodies produced using Chinese hamster ovary cells

Madabhushi, S. R., Podtelezhnikov, A. A., Murgolo, N., Xu, S., & Lin, H. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.01.023 · Cited by 27 · see citing works

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Peipp, M., van Bueren, J. J. L., Schneider‐Merck, T., Bleeker, W. K., Dechant, M., Beyer, T. D., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 223 · see citing works

Insights into fucose metabolism: SLC35C1-independent fucosylation discriminates against mannose-derived GDP-fucosePreprint

Skurska, E., Szulc, B., Maszczak‐Seneczko, D., Wiktor, M., Wiertelak, W., & Olczak, M. (2021) · Research Square · doi:10.21203/rs.3.rs-1096518/v1

Decreased fucose incorporation in cell surface carbohydrates is associated with inhibition of invasion

Bolscher, J. G. M., Bruyneel, E. A., van Rooy, H., et al. (1989) · Clinical & Experimental Metastasis · doi:10.1007/bf01753815 · Cited by 16 · see citing works

Elevated Porcine α-1,6 Fucose On GGTA1/CMAH Knockout Pigs Is a Target of Cytolytic Pre-Formed Human Antibodies.

Burlak, C., Butler, B., Travis, T. W., et al. (2014) · Transplantation · doi:10.1097/00007890-201407151-01381

Exogenous l ‐fucose protects the intestinal mucosal barrier depending on upregulation of FUT2‐mediated fucosylation of intestinal epithelial cells

Li, Y., Jiang, Y., Zhang, L., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002446rrrr · Cited by 44 · see citing works